- BIIB -0.57%
Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial
Yahoo Finance · 6 days ago
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- 197.96Add to watchlist-1.12 (-0.57%)As of Thu. Sep 12, 2024 3:01 PM EDT · Nasdaq Real Time Price (USD) · Market open
- Open199.05High199.26Low194.90
- Mkt Cap28.84BP/E (TTM)24.96Div & YieldN/A & N/A
- Prev. Close199.0952 Wk. Low189.4452 Wk. High269.43
What analysts are sayingTop storiesRelated stocks
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Sep 4, 2024 · Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). Please click here for Important Safety Information and full Prescribing Information for SPINRAZA in the U.S., or visit your respective country’s product website. About Biogen
Jun 7, 2021 · The Food and Drug Administration on Monday approved Biogen 's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people ...
